06/29/2017

The FDA approval of Tafinlar® (dabrafenib) in combination with Mekinist® (trametinib) to treat patients with metastatic NSCLC whose tumors express the BRAF V600E mutation.

The FDA approval of Tafinlar^® (dabrafenib) in combination with Mekinist^® (trametinib) to treat patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express the BRAF V600E mutation. The FDA granted Tafinlar + Mekinist Breakthrough Therapy designation in July, 2015, for the treatment of patients with advanced or metastatic BRAF V600E mutation-positive NSCLC who received previous treatment with chemotherapy.

For more information, click here.